{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:30Z","timestamp":1790208030487,"version":"4.1.0"},"reference-count":88,"publisher":"Georg Thieme Verlag KG","issue":"10","license":[{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thromb Haemost"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:p>Chronic inflammation plays a key role in the development and progression of atherosclerotic cardiovascular disease (ASCVD) and its complications. Despite the use of blood pressure-, lipid-, and glucose-lowering therapies as well as antithrombotic agents, the lifetime residual cardiovascular (CV) risk in patients with ASCVD remains high. Because chronic inflammation remains an unaddressed risk factor, anti-inflammatory therapy has the potential to further lower residual CV risk in these patients. Low-dose colchicine (0.5\u2009mg daily) has emerged as a promising low-cost oral anti-inflammatory therapy for this indication. In patients with chronic coronary syndrome (CCS), low-dose colchicine was well-tolerated and reduced the risk of myocardial infarction, stroke, coronary revascularization, and CV death. However, trials in patients with acute coronary syndrome (ACS) yielded conflicting results, and two trials in patients with ischemic stroke did not show a benefit. In patients with peripheral artery disease (PAD), preliminary observational data suggested a potential benefit, and a randomized trial is currently underway to examine its efficacy in reducing CV and limb events. The long-term safety data for low-dose colchicine in ASCVD are reassuring. Although pooled data from trials in ASCVD show a small (0.55%) absolute increase in the risk of hospitalization for gastrointestinal events, adverse signals were not observed for serious infection, cancer, or severe myotoxicity. In this article, we review the clinical studies of colchicine that examined its risk\u2013benefit for the prevention of CV events in patients with ASCVD, discuss clinical and research implications, and highlight knowledge gaps.<\/jats:p>","DOI":"10.1055\/a-2724-4543","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T23:16:11Z","timestamp":1761261371000},"page":"0991-1005","source":"Crossref","is-referenced-by-count":2,"title":["Current Evidence and Future Directions for Colchicine in the Prevention of Atherosclerotic Cardiovascular Disease"],"prefix":"10.1055","volume":"126","author":[{"given":"Aim\u00e9e M.H.","family":"van Zelm","sequence":"additional","affiliation":[{"name":"Department of Vascular Surgery, University Medical Center Utrecht, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aernoud T.L.","family":"Fiolet","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Medical Center Utrecht, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Hinchliffe","sequence":"additional","affiliation":[{"name":"Department of Vascular Surgery, University of Bristol, Bristol, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirley","family":"Jansen","sequence":"additional","affiliation":[{"name":"Department of Vascular and Endovascular Surgery, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia"},{"name":"Heart and Vascular Research Institute, Harry Perkins Institute of Medical Research, Perth, Western Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Teraa","sequence":"additional","affiliation":[{"name":"Department of Vascular Surgery, University Medical Center Utrecht, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noel C.","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Medicine, McMaster University, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2025,11,7]]},"reference":[{"issue":"08","key":"ref1","doi-asserted-by":"crossref","first-page":"e347","DOI":"10.1161\/CIR.0000000000001209","article-title":"2024 Heart Disease and Stroke Statistics: A Report of US and Global Data from the American Heart Association","volume":"149","author":"S S Martin","year":"2024","journal-title":"Circulation"},{"issue":"15","key":"ref2","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1093\/eurjpc\/zwad222","article-title":"Flexible addition of risk modifiers on top of SCORE2 to improve long-term risk prediction in healthy individuals","volume":"30","author":"J Auer","year":"2023","journal-title":"Eur J Prev Cardiol"},{"issue":"19","key":"ref3","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1093\/eurheartj\/ehp355","article-title":"Three-year follow-up and event rates in the international REduction of Atherothrombosis for Continued Health Registry","volume":"30","author":"M J Alberts","year":"2009","journal-title":"Eur Heart J"},{"issue":"04","key":"ref4","doi-asserted-by":"crossref","first-page":"786.e1","DOI":"10.1016\/j.ahj.2005.11.004","article-title":"The REduction of Atherothrombosis for Continued Health (REACH) Registry: An international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design","volume":"151","author":"E M Ohman","year":"2006","journal-title":"Am Heart J"},{"issue":"02","key":"ref5","doi-asserted-by":"crossref","first-page":"e066952","DOI":"10.1136\/bmjopen-2022-066952","article-title":"Cohort profile: The Utrecht Cardiovascular Cohort-Second Manifestations of Arterial Disease (UCC-SMART) Study-an ongoing prospective cohort study of patients at high cardiovascular risk in the Netherlands","volume":"13","author":"M C Castelijns","year":"2023","journal-title":"BMJ Open"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.amjcard.2023.03.025","article-title":"C-reactive protein and risk of cardiovascular events and mortality in patients with various cardiovascular disease locations","volume":"197","author":"P M Burger","year":"2023","journal-title":"Am J Cardiol"},{"issue":"06","key":"ref7","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.jvs.2009.09.044","article-title":"Suggested objective performance goals and clinical trial design for evaluating catheter-based treatment of critical limb ischemia","volume":"50","author":"M S Conte","year":"2009","journal-title":"J Vasc Surg"},{"issue":"03","key":"ref8","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.ejvs.2023.06.007","article-title":"Assessing limb outcomes in drug trials in peripheral artery disease: The need for a universal and pragmatic definition","volume":"66","author":"S Jansen","year":"2023","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"04","key":"ref9","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1097\/HJR.0b013e3283361ce6","article-title":"Patients with coronary, cerebrovascular or peripheral arterial obstructive disease differ in risk for new vascular events and mortality: The SMART study","volume":"17","author":"S Achterberg","year":"2010","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"issue":"24","key":"ref10","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1161\/CIRCULATIONAHA.118.035289","article-title":"Conceptual framework for addressing residual atherosclerotic cardiovascular disease risk in the era of precision medicine","volume":"137","author":"K V Patel","year":"2018","journal-title":"Circulation"},{"issue":"7855","key":"ref11","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/s41586-021-03392-8","article-title":"The changing landscape of atherosclerosis","volume":"592","author":"P Libby","year":"2021","journal-title":"Nature"},{"issue":"17","key":"ref12","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1016\/j.jacc.2018.08.1043","article-title":"Inflammation, immunity, and infection in atherothrombosis: JACC Review Topic of the Week","volume":"72","author":"P Libby","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"26","key":"ref13","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1093\/eurheartj\/ehaf210","article-title":"Colchicine for secondary prevention of vascular events: A meta-analysis of trials","volume":"46","author":"M A d'Entremont","year":"2025","journal-title":"Eur Heart J"},{"issue":"05","key":"ref14","first-page":"588","article-title":"Inflammation as a mechanism and therapeutic target in peripheral artery disease","volume":"38","author":"N C Chan","year":"2022","journal-title":"Can J Cardiol"},{"issue":"13","key":"ref15","first-page":"2525","article-title":"Inflammation during the life cycle of the atherosclerotic plaque","volume":"117","author":"P Libby","year":"2021","journal-title":"Cardiovasc Res"},{"issue":"02","key":"ref16","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJM199901143400207","article-title":"Atherosclerosis\u2013an inflammatory disease","volume":"340","author":"R Ross","year":"1999","journal-title":"N Engl J Med"},{"issue":"09","key":"ref17","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1056\/NEJMra2000317","article-title":"Atherosclerotic plaque healing","volume":"383","author":"R Vergallo","year":"2020","journal-title":"N Engl J Med"},{"issue":"12","key":"ref18","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1161\/CIRCRESAHA.114.302721","article-title":"Mechanisms of plaque formation and rupture","volume":"114","author":"J F Bentzon","year":"2014","journal-title":"Circ Res"},{"issue":"06","key":"ref19","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.jacc.2005.03.074","article-title":"Atherothrombosis and high-risk plaque: Part I: Evolving concepts","volume":"46","author":"V Fuster","year":"2005","journal-title":"J Am Coll Cardiol"},{"issue":"7347","key":"ref20","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nature10146","article-title":"Progress and challenges in translating the biology of atherosclerosis","volume":"473","author":"P Libby","year":"2011","journal-title":"Nature"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"107238","DOI":"10.1016\/j.vph.2023.107238","article-title":"Targeting residual inflammatory risk: The next frontier for atherosclerosis treatment and prevention","volume":"153","author":"P M Ridker","year":"2023","journal-title":"Vascul Pharmacol"},{"issue":"04","key":"ref22","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1161\/ATVBAHA.118.310958","article-title":"Novel antiatherosclerotic therapies","volume":"39","author":"P Libby","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"7293","key":"ref23","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/nature08938","article-title":"NLRP3 inflamasomes are required for atherogenesis and activated by cholesterol crystals that form early in disease","volume":"464","author":"P Duewell","year":"2010","journal-title":"Nature"},{"issue":"12","key":"ref24","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"P M Ridker","year":"2017","journal-title":"N Engl J Med"},{"issue":"08","key":"ref25","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1056\/NEJMoa1809798","article-title":"Low-dose methotrexate for the prevention of atherosclerotic events","volume":"380","author":"P M Ridker","year":"2019","journal-title":"N Engl J Med"},{"issue":"12","key":"ref26","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1056\/NEJMe1709904","article-title":"Targeting inflammation in coronary artery disease","volume":"377","author":"R A Harrington","year":"2017","journal-title":"N Engl J Med"},{"issue":"10","key":"ref27","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1161\/CIRCULATIONAHA.119.045256","article-title":"From CANTOS to CIRT to COLCOT to Clinic: Will all atherosclerosis patients soon be treated with combination lipid-lowering and inflammation-inhibiting agents?","volume":"141","author":"P M Ridker","year":"2020","journal-title":"Circulation"},{"issue":"01","key":"ref28","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1161\/CIRCULATIONAHA.121.056171","article-title":"Colchicine in cardiovascular disease: In-depth review","volume":"145","author":"S G Deftereos","year":"2022","journal-title":"Circulation"},{"issue":"11","key":"ref29","doi-asserted-by":"crossref","first-page":"687","DOI":"10.5694\/mja14.00846","article-title":"Colchicine\u2013a short history of an ancient drug","volume":"201","author":"N Nerlekar","year":"2014","journal-title":"Med J Aust"},{"issue":"18","key":"ref30","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1056\/NEJM197410312911804","article-title":"Colchicine therapy for familial Mediterranean fever. A double-blind trial","volume":"291","author":"C A Dinarello","year":"1974","journal-title":"N Engl J Med"},{"issue":"18","key":"ref31","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1056\/NEJM197410312911803","article-title":"A controlled trial of colchicine in preventing attacks of familial Mediterranean fever","volume":"291","author":"D Zemer","year":"1974","journal-title":"N Engl J Med"},{"issue":"03","key":"ref32","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1136\/ard.13.3.190","article-title":"History of the use of colchicum and related medicaments in gout; with suggestions for further research","volume":"13","author":"E F Hartung","year":"1954","journal-title":"Ann Rheum Dis"},{"issue":"14","key":"ref33","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1136\/heartjnl-2011-301306","article-title":"Efficacy and safety of colchicine for pericarditis prevention. Systematic review and meta-analysis","volume":"98","author":"M Imazio","year":"2012","journal-title":"Heart"},{"issue":"14","key":"ref35","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1042\/CS20160090","article-title":"Colchicine therapy in acute coronary syndrome patients acts on caspase-1 to suppress NLRP3 inflammasome monocyte activation","volume":"130","author":"S Robertson","year":"2016","journal-title":"Clin Sci (Lond)"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"175068","DOI":"10.1016\/j.ejphar.2022.175068","article-title":"Effect of colchicine on inflammatory markers in patients with coronary artery disease: A meta-analysis of clinical trials","volume":"927","author":"Z Pan","year":"2022","journal-title":"Eur J Pharmacol"},{"issue":"08","key":"ref37","doi-asserted-by":"crossref","first-page":"e002128","DOI":"10.1161\/JAHA.115.002128","article-title":"Colchicine acutely suppresses local cardiac production of inflammatory cytokines in patients with an acute coronary syndrome","volume":"4","author":"G J Mart\u00ednez","year":"2015","journal-title":"J Am Heart Assoc"},{"issue":"20","key":"ref38","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1161\/CIRCULATIONAHA.120.050560","article-title":"Colchicine attenuates inflammation beyond the inflammasome in chronic coronary artery disease: A LoDoCo2 proteomic substudy","volume":"142","author":"T SJ Opstal","year":"2020","journal-title":"Circulation"},{"issue":"04","key":"ref39","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/BF00194404","article-title":"Pharmacokinetics and absolute bioavailability of colchicine after i.v. and oral administration in healthy human volunteers and elderly subjects","volume":"46","author":"M Rochdi","year":"1994","journal-title":"Eur J Clin Pharmacol"},{"issue":"04","key":"ref40","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/clpt.1993.161","article-title":"Colchicine disposition in human leukocytes after single and multiple oral administration","volume":"54","author":"O N Chappey","year":"1993","journal-title":"Clin Pharmacol Ther"},{"issue":"01","key":"ref41","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0006-2952(96)00693-4","article-title":"Colchicine biotransformation by human liver microsomes. Identification of CYP3A4 as the major isoform responsible for colchicine demethylation","volume":"53","author":"T Tateishi","year":"1997","journal-title":"Biochem Pharmacol"},{"issue":"06","key":"ref42","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1177\/096032719201100612","article-title":"Toxicokinetics of colchicine in humans: Analysis of tissue, plasma and urine data in ten cases","volume":"11","author":"M Rochdi","year":"1992","journal-title":"Hum Exp Toxicol"},{"issue":"01","key":"ref43","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.amjmed.2021.07.025","article-title":"Consensus statement regarding the efficacy and safety of long-term low-dose colchicine in gout and cardiovascular disease","volume":"135","author":"P C Robinson","year":"2022","journal-title":"Am J Med"},{"issue":"19","key":"ref44","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in patients with chronic coronary disease","volume":"383","author":"S M Nidorf","year":"2020","journal-title":"N Engl J Med"},{"issue":"20","key":"ref45","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1161\/CIRCULATIONAHA.120.050771","article-title":"Colchicine in patients with acute coronary syndrome: The Australian COPS Randomized Clinical Trial","volume":"142","author":"D C Tong","year":"2020","journal-title":"Circulation"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0140-6736(24)00968-1","article-title":"Long-term colchicine for the prevention of vascular recurrent events in non-cardioembolic stroke (CONVINCE): a randomised controlled trial","volume":"404","author":"P Kelly","year":"2024","journal-title":"Lancet"},{"issue":"08","key":"ref47","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1136\/heartjnl-2015-308542","article-title":"Cardiovascular effects and safety of long-term colchicine treatment: Cochrane review and meta-analysis","volume":"102","author":"L G Hemkens","year":"2016","journal-title":"Heart"},{"issue":"01","key":"ref48","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13075-020-2120-7","article-title":"Adverse events during oral colchicine use: A systematic review and meta-analysis of randomised controlled trials","volume":"22","author":"S Stewart","year":"2020","journal-title":"Arthritis Res Ther"},{"issue":"07","key":"ref49","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.jacc.2023.05.055","article-title":"Low-dose colchicine for secondary prevention of coronary artery disease: JACC Review Topic of the Week","volume":"82","author":"K Nelson","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"ref50","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s40261-014-0238-6","article-title":"Single-dose, open-label study of the differences in pharmacokinetics of colchicine in subjects with renal impairment, including end-stage renal disease","volume":"34","author":"S Wason","year":"2014","journal-title":"Clin Drug Investig"},{"issue":"25","key":"ref51","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1056\/NEJM198706183162502","article-title":"Colchicine myopathy and neuropathy","volume":"316","author":"R W Kuncl","year":"1987","journal-title":"N Engl J Med"},{"issue":"06","key":"ref52","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0735-6757(98)90228-5","article-title":"Fatal colchicine overdose: Report of a case and review of the literature","volume":"16","author":"S T Milne","year":"1998","journal-title":"Am J Emerg Med"},{"issue":"03","key":"ref53","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/0049-0172(91)90003-I","article-title":"Colchicine intoxication: Clinical pharmacology, risk factors, features, and management","volume":"21","author":"C Putterman","year":"1991","journal-title":"Semin Arthritis Rheum"},{"issue":"05","key":"ref54","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3109\/15563650.2010.495348","article-title":"Colchicine poisoning: The dark side of an ancient drug","volume":"48","author":"Y Finkelstein","year":"2010","journal-title":"Clin Toxicol (Phila)"},{"issue":"28","key":"ref55","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1093\/eurheartj\/ehab115","article-title":"Efficacy and safety of low-dose colchicine in patients with coronary disease: A systematic review and meta-analysis of randomized trials","volume":"42","author":"A TL Fiolet","year":"2021","journal-title":"Eur Heart J"},{"issue":"11","key":"ref56","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s40261-022-01209-8","article-title":"The effect of years-long exposure to low-dose colchicine on renal and liver function and blood creatine kinase levels: Safety insights from the Low-Dose Colchicine 2 (LoDoCo2) Trial","volume":"42","author":"A van Broekhoven","year":"2022","journal-title":"Clin Drug Investig"},{"issue":"07","key":"ref57","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1056\/NEJMoa2405922","article-title":"Colchicine in acute myocardial infarction","volume":"392","author":"S S Jolly","year":"2025","journal-title":"N Engl J Med"},{"issue":"04","key":"ref58","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jacc.2012.10.027","article-title":"Low-dose colchicine for secondary prevention of cardiovascular disease","volume":"61","author":"S M Nidorf","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"26","key":"ref59","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"J C Tardif","year":"2019","journal-title":"N Engl J Med"},{"issue":"06","key":"ref60","doi-asserted-by":"crossref","first-page":"e079061","DOI":"10.1136\/bmj-2023-079061","article-title":"Colchicine in patients with acute ischaemic stroke or transient ischaemic attack (CHANCE-3): Multicentre, double blind, randomised, placebo controlled trial","volume":"385","author":"J Li","year":"2024","journal-title":"BMJ"},{"issue":"04","key":"ref61","first-page":"oeae062","article-title":"Colchicine improves clinical outcomes in patients with coronary disease, will it result in similar benefits in peripheral artery disease?","volume":"4","author":"P Heindel","year":"2024","journal-title":"Eur Heart J Open"},{"issue":"09","key":"ref62","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.mayocp.2024.05.004","article-title":"Effects of colchicine on major adverse limb and cardiovascular events in patients with peripheral artery disease","volume":"99","author":"D SH Lin","year":"2024","journal-title":"Mayo Clin Proc"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"118563","DOI":"10.1016\/j.atherosclerosis.2024.118563","article-title":"Association of colchicine use with cardiovascular and limb events in peripheral artery disease: Insights from a retrospective cohort study","volume":"398","author":"L Tramujas","year":"2024","journal-title":"Atherosclerosis"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"1244529","DOI":"10.3389\/fcvm.2023.1244529","article-title":"Colchicine and diabetes in patients with chronic coronary artery disease: Insights from the LoDoCo2 randomized controlled trial","volume":"10","author":"N Mohammadnia","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"ref65","first-page":"325527","article-title":"Effect of low-dose colchicine on pericoronary inflammation and coronary plaque composition in chronic coronary disease: a subanalysis of the LoDoCo2 trial","author":"A TL Fiolet","year":"2025","journal-title":"Heart"},{"issue":"42","key":"ref66","doi-asserted-by":"crossref","first-page":"4092","DOI":"10.1093\/eurheartj\/ehaa659","article-title":"Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)","volume":"41","author":"N Bouabdallaoui","year":"2020","journal-title":"Eur Heart J"},{"issue":"19","key":"ref67","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1161\/CIRCULATIONAHA.121.054610","article-title":"Colchicine in patients with acute coronary syndrome: Two-year follow-up of the Australian COPS randomized clinical trial","volume":"144","author":"D C Tong","year":"2021","journal-title":"Circulation"},{"issue":"38","key":"ref68","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1093\/eurheartj\/ehy310","article-title":"Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: Analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS)","volume":"39","author":"P M Ridker","year":"2018","journal-title":"Eur Heart J"},{"issue":"03","key":"ref69","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/ehjqcco\/qcad048","article-title":"Worldwide impact of COVID-19 on hospital admissions for non-ST-elevation acute coronary syndromes (NSTACS): a systematic review with meta-analysis of 553 038 cases","volume":"10","author":"F Sofi","year":"2024","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"issue":"03","key":"ref70","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/s44161-024-00600-2","article-title":"Implications and limitations of the CLEAR-SYNERGY trial for the use of low-dose colchicine in cardiovascular disease","volume":"4","author":"A Misra","year":"2025","journal-title":"Nat Cardiovasc Res"},{"issue":"03","key":"ref71","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/ehjcvp\/pvaf011","article-title":"CLEAR results, cloudy impact: colchicine's neutral role in ST-segment elevation myocardial infarction","volume":"11","author":"C Laudani","year":"2025","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"ref79","doi-asserted-by":"crossref","first-page":"102835","DOI":"10.1016\/j.eclinm.2024.102835","article-title":"Colchicine for secondary prevention of ischaemic stroke and atherosclerotic events: a meta-analysis of randomised trials","volume":"76","author":"A TL Fiolet","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"36","key":"ref85","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","article-title":"2024 ESC Guidelines for the management of chronic coronary syndromes","volume":"45","author":"C Vrints","year":"2024","journal-title":"Eur Heart J"},{"issue":"09","key":"ref86","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jacc.2023.04.003","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"82","author":"S S Virani","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"34","key":"ref87","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"F LJ Visseren","year":"2021","journal-title":"Eur Heart J"},{"issue":"22","key":"ref88","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1016\/j.jacc.2024.11.009","article-title":"2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"85","author":"S V Rao","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"ref89","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1161\/STR.0000000000000475","article-title":"2024 Guideline for the Primary Prevention of Stroke: A guideline from the American Heart Association\/American Stroke Association","volume":"55","author":"C Bushnell","year":"2024","journal-title":"Stroke"},{"issue":"07","key":"ref90","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1161\/STR.0000000000000375","article-title":"2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A guideline from the American Heart Association\/American Stroke Association","volume":"52","author":"D O Kleindorfer","year":"2021","journal-title":"Stroke"},{"issue":"24","key":"ref91","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1016\/j.jacc.2024.02.013","article-title":"2024 ACC\/AHA\/AACVPR\/APMA\/ABC\/SCAI\/SVM\/SVN\/SVS\/SIR\/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease: A report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"83","author":"H L Gornik","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"9678","key":"ref92","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","author":"C Baigent","year":"2009","journal-title":"Lancet"},{"issue":"09","key":"ref93","doi-asserted-by":"crossref","first-page":"100669","DOI":"10.1016\/j.jacadv.2023.100669","article-title":"Sex Differences in Cardiovascular Outcomes and Cholesterol-Lowering Efficacy of PCSK9 Inhibitors: Systematic Review and Meta-Analysis","volume":"2","author":"F B Rivera","year":"2023","journal-title":"JACC Adv"},{"issue":"05","key":"ref94","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1093\/ehjqcco\/qcaa045","article-title":"Cost-effectiveness of low-dose colchicine after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)","volume":"7","author":"M Samuel","year":"2021","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"issue":"01","key":"ref95","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/ehjqcco\/qcae021","article-title":"Cost-effectiveness of low-dose colchicine in patients with chronic coronary disease in The Netherlands","volume":"11","author":"A TL Fiolet","year":"2025","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"issue":"04","key":"ref96","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1093\/ehjcvp\/pvac005","article-title":"Facing the challenge of polypharmacy when prescribing for older people with cardiovascular disease. A review by the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy","volume":"8","author":"J Tamargo","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"11","key":"ref97","doi-asserted-by":"crossref","first-page":"e006977","DOI":"10.1161\/CIRCHEARTFAILURE.120.006977","article-title":"Polypharmacy in older adults hospitalized for heart failure","volume":"13","author":"O Unlu","year":"2020","journal-title":"Circ Heart Fail"},{"key":"ref98","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ijcard.2022.06.028","article-title":"Low-dose colchicine and high-sensitivity C-reactive protein after myocardial infarction: A combined analysis using individual patient data from the COLCOT and LoDoCo-MI studies","volume":"363","author":"M Sun","year":"2022","journal-title":"Int J Cardiol"},{"issue":"9844","key":"ref99","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0140-6736(12)60572-8","article-title":"Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study","volume":"380","author":"M Tonelli","year":"2012","journal-title":"Lancet"},{"issue":"04","key":"ref100","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s40744-025-00772-8","article-title":"Prophylaxis of gout flares in patients with renal impairment: Dosing adjustments with colchicine oral solution informed by a pharmacokinetic model","volume":"12","author":"J Shah","year":"2025","journal-title":"Rheumatol Ther"},{"issue":"06","key":"ref101","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1007\/s13300-025-01738-3","article-title":"Advancing cardiovascular, kidney, and metabolic medicine: A narrative review of insights and innovations for the future","volume":"16","author":"K Fernando","year":"2025","journal-title":"Diabetes Ther"}],"container-title":["Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2724-4543.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T23:12:10Z","timestamp":1790205130000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2724-4543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,23]]},"references-count":88,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,9,23]]},"published-print":{"date-parts":[[2026,10]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2724-4543","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0340-6245","2567-689X"],"issn-type":[{"value":"0340-6245","type":"print"},{"value":"2567-689X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10,23]]},"published":{"date-parts":[[2025,10,23]]}}}